Management of recurrent nasopharyngeal carcinoma: current perspectives(48 visite) Perri F, Della Vittoria Scarpati G, Caponigro F, Ionna F, Longo F, Buonopane S, Muto P, Di Marzo M, Pisconti S, Solla R
Oncotargets Ther (ISSN: 1178-6930linking), 2019 Feb 26; 12: 1583-1591.
Tipo di articolo: Journal Article
Impact factor: 2.272, Impact factor a 5 anni: 2.235
*** IBB - CNR *** Head and Neck/Sarcoma Medical Oncology Unit, INT IRCCS G Pascale, Naples, Italy, email@example.com. Department of Otolaryngology and Head and Neck Surgery, INT IRCCS G Pascale, Naples, Italy. Department of Radiation Therapy, INT IRCCS G Pascale, Naples, Italy. Department of Abdominal Surgery, INT IRCCS G Pascale, Naples, Italy. Italian National Research Council, Institute of Biostructure and Bioimaging, Naples, Italy.
Nasopharyngeal carcinoma is a rare disease in Western countries. Nevertheless, its incidence in China, Singapore, and other Eastern countries reaches 20 cases per 100,000 people. Being an extremely chemo- and radiosensitive disease, upfront treatment often consists in the association of intensity-modulated radiation therapy and concurrent cisplatin. Unfortunately, about 20% of the patients suffer from a radioresistant disease which recurs after upfront therapy. For these patients, mainly available therapeutic options consist in systemic therapy, in particular poly-chemotherapy. In those showing a single locoregional recurrence, chemotherapy is not considered to be the preferred approach and other different strategies may be employed. Re-irradiation and surgery are strategies that are always used more often, albeit related to high risk of morbidity. Immunotherapy and targeted therapy, such as heavy ions-based re-irradiations, are experimental but very intriguing options.<br>